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results
study I
After a median follow-up of 140 months, 10/30 patients are still
alive. Median survival was reached after 104 months. Five- and
10-year OS estimates were 67% [95% conﬁdence interval (CI)
52% to –86%] and 42% (95% CI 28% to –65%) (Figure 1). EFS
estimates after 5 and 10 years were 67% (95% CI 52% to 86%) and
40% (95% CI 25% to 62%), respectively. In the per-protocol ana-
lysis, median survival was reached after 122 months. Five- and
10-year OS probability was 83% (95% CI 69%–100%) and 56%
(95% CI 39%–81%) and EFS probability after 5 and 10 years was
83% (95% CI 69%–100%) and 52% (95% CI 35%–77%), respect-
ively.
study II
After a median follow-up of 72 months, 9/13 patients are still
alive. The median survival was not reached at the time of last
follow-up. Both 2- and 5-year OS estimates were 77% (95% CI
57%–100%) (Figure 2). Two- and 5-year EFS estimates were 77%
(95% CI 57%–100%) and 70% (95% CI 48%–100%), respectively.
In the per-protocol population, 8/11 patients are still alive. Both
2- and 5-year OS estimates were 82% (95% CI 62%–100%);
2- and 5-year EFS estimates were 82% (95% CI 62%–100%) and
73% (95% CI 51%–100%), respectively.
pooled analysis of the whole cohort
In the entire intention-to-treat group (N = 43), after a follow-up
of 110 months, the median OS was reached at 104 months.
Two- and 5-year OS was 81% (95% CI 71%–94%) and 70%
(95% CI 57%–85%), respectively (supplemental Figure S2, avail-
able at Annals of Oncology online). Two- and 5-year EFS was
81% (95% CI 70%–94%) and 67% (95% CI 55%–83%), respect-
ively. In the per-protocol analysis, the median OS was reached
after 122 and median EFS after 104 months. The estimated
5-year OS and EFS was 82% (95% CI 71%–96%) and 79% (95%
CI 67%–94%), respectively. In multivariate Cox regression ana-
lysis, neither age [hazard ratio (HR) = 1.55, 95% CI 0.95–2.55,
P = 0.08] nor KPS (HR = 1.04, 95% CI 0.83–1.30, P = 0.7284)
had a signiﬁcant impact on survival. However, the HR and the
rather small P value for the coefﬁcient age suggest a trend that
with higher age the survival probability decreases.
relapse from CR
Of those patients achieving CR, in study I, after the last follow-
up, additional four patients relapsed (all together 10/25; 40%,
95% CI 22%–61%). Of those, only one was successfully salvaged
with a second HCT–ASCT and is ongoing CR. Regarding the
per-protocol population from study I, the overall relapse rate
was lower (7/22; 32%, 95% CI 0.15%–0.55%). In study II, previ-
ously one patient was reported to suffer from relapse (CNS and
systemic) after achieving CR. Now, one additional female
patient relapsed (altogether 2/9; 22%, 95%, CI 4%–60%), but she
was successfully salvaged by immuno-polychemotherapy (ritux-
imab, MTX, lomustine, and procarbazine).
In the entire cohort, 12 of 34 patients who achieved CR
relapsed (35%; 95% CI 20%–54%) and of those, six relapsed
5 years after diagnosis (18%; 95% CI 7%–35%). The relapse rate
in the per-protocol population was lower, here, only 9 of
30 patients who achieved CR relapsed (30%; 95% CI 15%–50%).
Figure 3 illustrates the cumulative incidence function of the
probability to die of PCNSL with other causes of death as com-
peting risk in the per-protocol population. The estimated risk of
death due to PCNSL after 5 years was 15% compared with 3% of
death due to other cause.
long-term survivors (over 5 years)
The characteristics of 28 patients who survived 5 years and longer
after diagnosis are summarized in supplemental Table S1 (avail-
able at Annals of Oncology online). Of those, only two who experi-
enced a relapse were successfully salvaged and are still alive
(patient 20 and 23). One female patient (44 years of age) devel-
oped late onset neurotoxicity during follow-up. She was irradiated
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because of only obtaining partial remission after HCT–ASCT
(patient 25). One patient died due to severe neurotoxicity (patient
2). Altogether, six patients relapsed after > 5 years. During ﬁrst-
line treatment, ﬁve of these six patients received HCT–ASCT
according to study protocol (one refused WBRT after HCT–
ASCT, patient 20) and one patient (patient 8) was only irradiated
due to renal failure developed after the second HD-MTX applica-
tion (stable disease at that time, CR after WBRT). In these ﬁve
patients who received HCT–ASCT, ﬁrst CR was observed (i)
during induction treatment with HD-MTX (N = 2, patients 5 and
20), (ii) after HCT–ASCT (N = 1, patient 10), and (iii) after
WBRT (N = 2, patients 2 and 3). There were no apparent differ-
ences compared with all other patients regarding histology.
WBRT versus no-WBRT
We dichotomized our cohort in patients who received WBRT
(N = 30, for consolidation N = 26, for salvage N = 4) and those
who did not (N = 13) to describe the association between WBRT
and clinical apparent neurotoxicity. Of those eight (19%) patients
who developed neurotoxicity during the entire follow-up, all were
irradiated [N = 7 (as planned in study I), N = 1 (from study II due
to partial response (PR) after HCT–ASCT)]. None of the patients
who solely underwent HCT–ASCT developed neurotoxicity.
Furthermore, regarding efﬁcacy, patients who received HCT–
ASCT without consolidating WBRT (N = 10; two from study I,
eight from study II) achieved a response rate of 100% (nine CR,
one PR); 2- and 5-year OS rates were 80% (95% CI 59 to 100) and
70% (95% CI 47 to 100), respectively.
discussion
The present study provides long-term data of patients with
newly diagnosed PCNSL who were treated according to our pre-
viously published HCT–ASCT containing protocols [13, 14]. So
far, eight studies (including ours) reported outcome after HCT–
ASCT containing regimens for ﬁrst-line treatment in PCNSL
patients [13, 14, 17–22] (supplemental Table S2, available at
Annals of Oncology online). Median follow-up ranged between
15 and 63 months (number of patients, 6–30) and conditioning
regimens as well as survival rates varied strongly among the
studies. To our best knowledge, no other study has yet reported
comparable long-term data as reported in the present analysis
regarding the treatment approach using HCT–ASCT in newly
diagnosed PCNSL and for the population up to 65 years, no su-
perior outcome data were published.
According to a recent review, only few studies reached a
median OS of 60 months or longer [1]. Recently published
long-term follow-up data of the ‘Bonn Protocol’ (median
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Figure 2. Overall survival study II (N = 13). HCT–ASCT, high-dose chemo-
therapy followed by autologous stem-cell transplantation.
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Figure 1. Overall survival study I (N = 30). HCT–ASCT, high-dose chemo-
therapy followed by autologous stem-cell transplantation.
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Figure 3. Cumulative incidence rates of death due to primary central
nervous system lymphoma with death due to other cause as competing risk
in the per-protocol population (N = 34).
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follow-up 100 months for surviving patients) show a median OS
of 54 months for the whole study population, but the median
OS for patients younger than 60 years (N = 30) has not been
reached yet [23]. Another recent publication reports a median
OS of 33 months after a median follow-up of 83 months;
however, this prospective multicenter trial was stopped due to
toxicity and slow accrual [24]. These examples reﬂect the still
existing heterogeneity of outcomes which may be caused by
several differences regarding treatment protocols, study design
(single center versus multicenter), type of analysis (retrospective
versus prospective), age limit but also baseline risk factors. In
fact, besides age and KPS, which are both wellestablished clinical
prognostic factors, several other factors such as serological
markers but also pharmacokinetic parameters of MTX have
been proposed to potentially identify risk groups [25–27], but
most of these ﬁndings still lack external validation from larger
cohorts. Another cause of the observed heterogeneity is of
course random variability due to the relatively small numbers of
patients. However, with all these limitations, the now achieved
median OS of 104 months for patients up to 65 years in our
cohort is encouraging. Unfortunately, late relapses still occurred
and one additionally needs to consider the fact that patients
regarded eligible for this aggressive treatment approach are still a
selected subpopulation and do not represent the majority of
PCNSL patients. Especially elderly patients above 65 years who
comprise about 50% of PCNSL patients are mostly not eligible
for HCT–ASCT and are referred to other treatment regimens
[28], but thorough clinical baseline risk evaluation beyond age
should be done and if elderly patients have a good performance
status, they maybe also considered as candidates for HCT–ASCT.
It is known that substantial proportions of patients who achieve
CR experience relapse mostly during the ﬁrst 2 years after diagno-
sis [9]. Nayak et al. recently published comprehensive data from
378 PCNSL patients; of those, 268 achieved a CR and 230 of them
relapsed (86%; 95% CI 81%–90%). With regard to the narrow CI,
these data give a rather good estimate of the true relapse rate. The
authors further report that relapses after 5 years in CR were rare
but did occur in 3.7% [8]. Compared with the overall relapse rate,
our data compare favorably well with the data reported by Nayak
et al.; however, because recurrence occurred later, our rate of
patients who relapsed after 5 years is higher (18%) and only one of
our patients with such late relapse has successfully been salvaged
with a second HCT–ASCT containing a busulfan conditioning
regimen and is in ongoing CR [29]. It seems that even after an
upfront aggressive treatment approach, such as HCT–ASCT, some
clonal malignant cells persist within the organism and patients are
still at risk for relapse even after 5 years and longer.
Although WBRT is effective in disease control, the risk for
short- and long-term neurotoxicity as well as the low positive
impact on OS has recently questioned its role in ﬁrst-line therapy
[5, 7], but data from the recent randomized non- inferiority trial
need to be taken with care since it was under powered and the in-
duction treatment mainly based on HDMTX monotherapy [7,
30]. In fact, dose-reduced WBRT (23.4 Gy) is reported to be not
associated with neurocognitive decline but still excellent disease
control for patients achieving CR after treatment according to the
R-MPV regimen (rituximab, MTX, procarbazine, and vincristine)
[31]. On the other hand, Bessel et al. [32] reported compromised
disease control after reducing the WRBT dose from 45 to 30.6
Gy, but the comparison between these two cohorts is difﬁcult
since induction polychemotherapies varied. As previously
reported, the rate of clinical apparent neurotoxicity in our ﬁrst
study was relatively high (16.7%) in patients receiving both,
HCT–ASCT and hyperfractionated WBRT [13]. Unfortunately,
the rate in patients from study I increased during long-term
follow-up to 23.3%. One limitation of this analysis was the lack of
prospective standardized testing for neurocognition at baseline
and during follow-up, thus the reported risk for neurotoxicity
might even be underestimated. However, in study II, in order to
decrease the risk of neurotoxicity without lacking efﬁcacy, we
improved the protocol by adding another cycle of cytarabine/
thiotepa before stem-cell harvest and by doubling the thiotepa cu-
mulative dose (4 × 5 mg/kg) within the conditioning regimen. In
contrast to the earlier study, all patients were supposed to proceed
to HCT–ASCT irrespective of their response to HD-MTX. The
OS of study II was similar to the previous study with obligatory
WBRT and we observed only one female patient developing
severe neurotoxicity after being irradiated because of PR after
chemotherapy. Of note, the 3-year OS prognosis (82%) of the
per-protocol analysis of study II is comparable to that estimated
for patients suffering from systemic aggressive diffuse large cell b-
cell lymphoma who were at low to intermediate risk (3-year OS
81%) and treated in the rituximab era [33]. Granted treatment-
related mortality (TRM) is an issue to be considered when HCT–
ASCT is applied in ﬁrst-line therapy, but in both studies, we
observed no deaths in association with HCT–ASCT. Additionally,
following a systematic review of HCT–ASCT in systemic lymph-
oma, estimated TRM of 6% was not increased compared with
standard chemotherapy [34]. Therefore, basing on our data, not
only with regard to the lower risk of neurotoxicity but also the sys-
temic approach of eliminating residual lymphoma cells in all pos-
sible chemotherapy sanctuaries including the cerebrospinal ﬂuid,
HCT–ASCT could be an effective alternative to WBRT as consoli-
dation therapy. Nevertheless, results from our national multicenter
trial that has recently ﬁnished recruiting (N = 81) need to be
awaited. In this trial, rituximab was added to the induction treat-
ment and WBRT was restricted to those who did not achieve CR
after HCT–ASCT (NCT00647049) in accordance to study II.
Sequential HD-MTX-based chemotherapy followed by carmus-
tine/thiotepa-containing HCT–ASCT is a promising treatment
option leading to remarkable median survival rates of almost 9
years in eligible patients. The role of HCT–ASCT compared with
WBRT as consolidation in ﬁrst-line therapy is currently under in-
vestigation in an international randomized trial (NCT01011920),
which also evaluates three different combinations of induction
treatments for efﬁcacy and safety. With the improvement of chemo-
therapy protocols for PCNSL, another question that should be
addressed in the future is whether HCT–ASCT is really superior to
a potent immuno-polychemotherapy combination or may be de-
ferred and saved as an option in case of relapse.
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